Product Images Sapropterin Dihydrochloride

This is a graph showing the Blood Phe Level (umol/L) for participants treated with Sapropterin Dihydrochloride compared to those given a Placebo during a study that lasted six weeks. The graph indicates a significant decrease in Blood Phe Level for those using Sapropterin Dihydrochloride when compared to the Placebo group. The X-axis shows the study visits from week -2 to week 6, and the Y-axis shows the Blood Phe Level in umol/L.*

This appears to be a clinical study evaluating the effectiveness of Sapropterin Dihydrochloride in reducing blood Phe level, as compared to a placebo. The results suggest a statistically significant difference (p < 0.001) in Phe level reduction between the treatment and placebo groups over a period of 6 weeks. The study design involved multiple visits during this period, with measurements taken at each visit.*

This is a medication called Sapropterin Dihydrochloride, which comes in tablet form for oral consumption. Each tablet contains 100 mg of sapropterin dihydrochloride, which is equivalent to 76.8 mg of sapropterin. It is a prescription drug and is meant to be taken only under the supervision of a physician. The recommended dosage is included in the physician package insert. It should be kept out of reach of children and protected from moisture. It is manufactured by Par Pharmaceutical in Nut Ridge, NY, USA, and is also produced in Udupakkam, Kelambakkam - 603 103, India.*